Status:
COMPLETED
A Study to Assess Treatment Outcomes of abobotulinumtoxinA and onabotulinumtoxinA Treatments in Real Life Practice in Toxin-naïve Adult Patients With Limb Spasticity.
Lead Sponsor:
Ipsen
Conditions:
Spasticity Related to Any Cause Except Cerebral Palsy
Eligibility:
All Genders
18+ years
Brief Summary
The aim of the study is to describe treatment outcomes of abobotulinumtoxinA (aboBoNT-A) and onabotulinumtoxinA (onaBoNT-A) treatments, after one injection of either treatment, in toxin-naïve adult pa...
Eligibility Criteria
Inclusion
- Inclusion Criteria :
- Patient diagnosed with spasticity related to any cause except cerebral palsy.
- Patient initiated on treatment with either onaBoNT-A or aboBoNT-A during the study enrolment periods.
- Patient is an adult aged ≥18 years old at the time of the first BoNT-A injection for spasticity
- Patient has not received treatment with any type of BoNT-A 6 months prior to initiation of onaBoNT-A or aboBoNT-A. For patients with multiple courses of BoNT-A, separated by a gap of 6 months, only the first course will be evaluated in this study.
- Patient is being treated at Haywood Hospital at index date and during follow-up for up to 24 weeks post-index date, with medical records available for review.
- Exclusion Criteria :
- Patient is participating in an interventional clinical trial of an investigational medicinal product for the treatment of spasticity at index date and/or during follow-up.
Exclusion
Key Trial Info
Start Date :
January 11 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 30 2021
Estimated Enrollment :
114 Patients enrolled
Trial Details
Trial ID
NCT04396704
Start Date
January 11 2021
End Date
March 30 2021
Last Update
May 21 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
North Staffordshire Rehabilitation Centre. Midlands Partnership NHS Foundation Trust.
Stafford, United Kingdom, ST6 7AG